InvestorsHub Logo
Followers 29
Posts 2180
Boards Moderated 0
Alias Born 12/13/2016

Re: None

Thursday, 03/07/2024 4:40:46 PM

Thursday, March 07, 2024 4:40:46 PM

Post# of 460131
Alzheimer's future sales forecast....that is shortly in our future starting in Europe!

-------------

Despite Leqembi's launch pains, Eisai projects Alzheimer's med will reach $8.8B in the long run

By Fraiser Kansteiner

By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion). In the near term, the company is dealing with some launch hurdles.
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News